Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives $14.80 Average Price Target from Brokerages

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) has earned an average recommendation of "Buy" from the six analysts that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $14.80.

A number of equities analysts have weighed in on ACHV shares. Raymond James started coverage on shares of Achieve Life Sciences in a research note on Friday, September 27th. They set a "strong-buy" rating and a $20.00 price target on the stock. RODMAN&RENSHAW raised Achieve Life Sciences to a "strong-buy" rating in a research report on Thursday, November 14th. Finally, Rodman & Renshaw initiated coverage on Achieve Life Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $12.00 price target for the company.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ACHV. Bank of New York Mellon Corp acquired a new position in shares of Achieve Life Sciences during the second quarter worth $482,000. Geode Capital Management LLC lifted its holdings in Achieve Life Sciences by 6.9% in the 3rd quarter. Geode Capital Management LLC now owns 749,109 shares of the biopharmaceutical company's stock worth $3,552,000 after buying an additional 48,474 shares in the last quarter. Rhumbline Advisers acquired a new position in Achieve Life Sciences in the 2nd quarter worth $197,000. Barclays PLC boosted its position in Achieve Life Sciences by 303.1% in the 3rd quarter. Barclays PLC now owns 47,655 shares of the biopharmaceutical company's stock valued at $226,000 after buying an additional 35,832 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Achieve Life Sciences by 6.8% during the third quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company's stock valued at $2,045,000 after acquiring an additional 27,419 shares in the last quarter. Institutional investors and hedge funds own 33.52% of the company's stock.

Achieve Life Sciences Trading Up 0.3 %

Achieve Life Sciences stock traded up $0.01 during trading on Friday, hitting $3.70. The company's stock had a trading volume of 178,502 shares, compared to its average volume of 169,601. The stock's fifty day moving average is $4.29 and its 200 day moving average is $4.53. Achieve Life Sciences has a 1-year low of $3.42 and a 1-year high of $5.59. The stock has a market capitalization of $127.24 million, a price-to-earnings ratio of -3.27 and a beta of 1.58. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.78 and a current ratio of 6.78.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.10). During the same quarter in the prior year, the business earned ($0.34) EPS. As a group, equities research analysts predict that Achieve Life Sciences will post -1.17 EPS for the current year.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.